Literature DB >> 15172988

Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.

Mark A Rubin1, Sooryanarayana Varambally, Rameen Beroukhim, Scott A Tomlins, Daniel R Rhodes, Pamela L Paris, Matthias D Hofer, Martina Storz-Schweizer, Rainer Kuefer, Jonathan A Fletcher, Bae-Li Hsi, Jennifier A Byrne, Kenneth J Pienta, Colin Collins, William R Sellers, Arul M Chinnaiyan.   

Abstract

Gains in the long arm of chromosome 8 (8q) are believed to be associated with poor outcome and the development of hormone-refractory prostate cancer. Based on a meta-analysis of gene expression microarray data from multiple prostate cancer studies (D. R. Rhodes et al., Cancer Res 2002;62:4427-33), a candidate oncogene, Tumor Protein D52 (TPD52), was identified in the 8q21 amplicon. TPD52 is a coiled-coil motif-bearing protein, potentially involved in vesicle trafficking. Both mRNA and protein levels of TPD52 were highly elevated in prostate cancer tissues. Array comparative genomic hybridization and amplification analysis using single nucleotide polymorphism arrays demonstrated increased DNA copy number in the region encompassing TPD52. Fluorescence in situ hybridization on tissue microarrays confirmed TPD52 amplification in prostate cancer epithelia. Furthermore, our studies suggest that TPD52 protein levels may be regulated by androgens, consistent with the presence of androgen response elements in the upstream promoter of TPD52. In summary, these findings suggest that dysregulation of TPD52 by genomic amplification and androgen induction may play a role in prostate cancer progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172988     DOI: 10.1158/0008-5472.CAN-03-3881

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines.

Authors:  Nifang Niu; Yuxin Qin; Brooke L Fridley; Junmei Hou; Krishna R Kalari; Minjia Zhu; Tse-Yu Wu; Gregory D Jenkins; Anthony Batzler; Liewei Wang
Journal:  Genome Res       Date:  2010-10-05       Impact factor: 9.043

2.  Whole transcriptome amplification for gene expression profiling and development of molecular archives.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Rajal B Shah; Mark A Rubin; Eric Bruening; Vladimir Makarov; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

3.  Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues.

Authors:  Beatrice S Knudsen; April N Allen; Dale F McLerran; Robert L Vessella; Jonathan Karademos; Joan E Davies; Botoul Maqsodi; Gary K McMaster; Alan R Kristal
Journal:  J Mol Diagn       Date:  2008-02-14       Impact factor: 5.568

4.  Lentivirus-mediated TPD52L2 depletion inhibits the proliferation of liver cancer cells in vitro.

Authors:  Ze-Ya Pan; Yun Yang; Hao Pan; Jin Zhang; Hui Liu; Yuan Yang; Gang Huang; Lei Yin; Jian Huang; Wei-Ping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  Human RecQL4 helicase plays critical roles in prostate carcinogenesis.

Authors:  Yanrong Su; Jarah A Meador; Gloria M Calaf; Luca Proietti De-Santis; Yongliang Zhao; Vilhelm A Bohr; Adayabalam S Balajee
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

6.  Targeting monoamine oxidase A in advanced prostate cancer.

Authors:  Vincent Flamand; Hongjuan Zhao; Donna M Peehl
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

7.  Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.

Authors:  Sooryanarayana Varambally; Bharathi Laxman; Rohit Mehra; Qi Cao; Saravana M Dhanasekaran; Scott A Tomlins; Jill Granger; Adaikkalam Vellaichamy; Arun Sreekumar; Jianjun Yu; Wenjuan Gu; Ronglai Shen; Debashis Ghosh; Lorinda M Wright; Raleigh D Kladney; Rainer Kuefer; Mark A Rubin; Claus J Fimmel; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

8.  Characterizing the cancer genome in lung adenocarcinoma.

Authors:  Barbara A Weir; Michele S Woo; Gad Getz; Sven Perner; Li Ding; Rameen Beroukhim; William M Lin; Michael A Province; Aldi Kraja; Laura A Johnson; Kinjal Shah; Mitsuo Sato; Roman K Thomas; Justine A Barletta; Ingrid B Borecki; Stephen Broderick; Andrew C Chang; Derek Y Chiang; Lucian R Chirieac; Jeonghee Cho; Yoshitaka Fujii; Adi F Gazdar; Thomas Giordano; Heidi Greulich; Megan Hanna; Bruce E Johnson; Mark G Kris; Alex Lash; Ling Lin; Neal Lindeman; Elaine R Mardis; John D McPherson; John D Minna; Margaret B Morgan; Mark Nadel; Mark B Orringer; John R Osborne; Brad Ozenberger; Alex H Ramos; James Robinson; Jack A Roth; Valerie Rusch; Hidefumi Sasaki; Frances Shepherd; Carrie Sougnez; Margaret R Spitz; Ming-Sound Tsao; David Twomey; Roel G W Verhaak; George M Weinstock; David A Wheeler; Wendy Winckler; Akihiko Yoshizawa; Soyoung Yu; Maureen F Zakowski; Qunyuan Zhang; David G Beer; Ignacio I Wistuba; Mark A Watson; Levi A Garraway; Marc Ladanyi; William D Travis; William Pao; Mark A Rubin; Stacey B Gabriel; Richard A Gibbs; Harold E Varmus; Richard K Wilson; Eric S Lander; Matthew Meyerson
Journal:  Nature       Date:  2007-11-04       Impact factor: 49.962

9.  Tumor protein D54 is a negative regulator of extracellular matrix-dependent migration and attachment in oral squamous cell carcinoma-derived cell lines.

Authors:  Yoshiki Mukudai; Seiji Kondo; Atsushi Fujita; Yasuto Yoshihama; Tatsuo Shirota; Satoru Shintani
Journal:  Cell Oncol (Dordr)       Date:  2013-03-26       Impact factor: 6.730

10.  Defining aggressive prostate cancer using a 12-gene model.

Authors:  Tarek A Bismar; Francesca Demichelis; Alberto Riva; Robert Kim; Sooryanarayana Varambally; Le He; Jeff Kutok; Jonathan C Aster; Jeffery Tang; Rainer Kuefer; Matthias D Hofer; Phillip G Febbo; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.